下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>
多维分析
公司估值 资金追踪 卖空分析
00460 四环医药
1.110
-0.010-0.89%
显示同比
不显示
隐藏空行
(FY)2021/12/31(Q6)2021/06/30(FY)2020/12/31(Q6)2020/06/30
Per Share IndicaTor
Operating Cash Flow Per Share
205.91% 0.0872 2396.33% 0.0782 -82.95% 0.0285 -97.9% 0.0031
Cash Flow Per Share
319.5% 0.1414 136.55% 0.0034 -130.3% -0.0644 -104.79% -0.0093
Operating Income Per Share
39.49% 0.4315 98.84% 0.2425 -9.15% 0.3093 -38.91% 0.122
Net Asset Per Share
-5.86% 1.086 25.48% 1.2515 1.82% 1.1536 -19.82% 0.9974
Basic Earning Per Share
-9% 0.0541 348.85% 0.0776 118.29% 0.0594 107.13% 0.0173
Diluted  Earning Per Share
-9.62% 0.0537 346.07% 0.0772 118.29% 0.0594 107.13% 0.0173
Profitability
Gross Profit Ratio
-4.24% 74.394% 3.2% 76.925% -2.27% 77.690% -9.43% 74.540%
Operating Profit Ratio
-27.33% 23.211% 55.45% 46.453% 137.56% 31.942% 128.93% 29.884%
Net Profit Ratio
-65.95% 7.072% 127.76% 31.156% 121.75% 20.773% 111.58% 13.680%
Earning Before Tax Ratio
-52.48% 14.768% 49.98% 42.967% 136.37% 31.078% 127.58% 28.650%
ROE
-6.88% 4.840% 296.69% 6.460% 121.17% 5.197% 109.25% 1.629%
ROA
-19.5% 3.066% 288.69% 4.496% 119.64% 3.809% 108.39% 1.157%
Yield Quality
Operating Profit To Total Profits
52.92% 157.174% 3.65% 108.112% -- 102.779% -- 104.308%
Tax To Total Profits
82.19% 52.110% -37.76% 27.489% -- 28.601% -- 44.164%
Operating Cash To Total Revenue
119.31% 20.214% 1155.29% 32.251% -81.23% 9.217% -96.57% 2.569%
Capital Structure
Debt Assets Ratio
55.41% 36.877% -20.39% 25.347% 13.46% 23.729% 44.16% 31.838%
Equity Multipler
23.29% 1.7498 -4.45% 1.4534 8.46% 1.4193 14.52% 1.521
Debt Equity Ratio
87.78% 58.421% -27.31% 33.954% 17.64% 31.112% 64.78% 46.710%
Current Assets To tatal Assets
8.78% 53.405% -5.37% 50.099% -2.11% 49.097% 9.09% 52.940%
Non Current Assets To Total Assets
-8.46% 46.595% 6.04% 49.901% 2.12% 50.903% -8.57% 47.060%
Current Liabilities To tatal Liabilities
-40.71% 46.802% -20.88% 71.894% -8.2% 78.931% 2.06% 90.862%
Non Current Liabilities To Total Liabilities
152.5% 53.198% 207.57% 28.106% 50.34% 21.069% -16.73% 9.138%
Solvency
Current Ratio
18.04% 3.0943 50.23% 2.7492 -6.01% 2.6213 -25.85% 1.83
Quick Ratio
16.13% 2.8084 47.72% 2.5322 -7.26% 2.4184 -26.53% 1.7141
Operating Profit To Current Liabilities
-5.22% 0.3054 309.23% 0.3398 129.67% 0.3222 113.08% 0.083
Operrating Cash Flow To Current Liabilities
186.03% 0.2659 3204.52% 0.2359 -85.18% 0.093 -98.45% 0.0071
Share Equity Without Minority Interest To Total Liabilities
-47.81% 1.5497 31.45% 2.7144 -18.74% 2.9692 -39.43% 2.065
Operating Cash Flow To Total Liabilities
69.6% 0.1245 2514.89% 0.1696 -86.39% 0.0734 -98.42% 0.0065
Operating Profit To Total Liabilities
-43.8% 0.1429 223.8% 0.2443 127.24% 0.2543 113.35% 0.0755
Operating Capacity
Inventory Turnover(T)
12.79% 1.4081 33.09% 0.8335 -24.28% 1.2485 -28.92% 0.6263
Current Assets Turnover(T)
17.93% 0.4714 79.19% 0.2826 -15.36% 0.3998 -40.76% 0.1577
Fixed Assets Turnover(T)
19.68% 1.0497 64.53% 0.6188 -15.31% 0.8771 -37.06% 0.3761
Total Assets Turnover(T)
22.2% 0.2423 72.45% 0.1402 -2.48% 0.1983 -28.34% 0.0813
Growth Ability
Operating Revenue GR 3Y
292.35% 20.901% 268.16% 51.175% -14.31% -10.866% -285.7% -30.433%
Gross Income GR 3Y
339.4% 10.295% 268.52% 44.925% -191.63% -4.300% -161.54% -26.659%
Operating Profit GR 3Y
-10.98% -59.589% 92.83% -4.955% 75.03% -53.694% 77.07% -69.074%
EBT GR 3Y
-32.32% -74.113% 86.17% -9.849% 73.88% -56.009% 75.31% -71.213%
Net Profit GR 3Y
-29.75% -85.146% 72.02% -23.421% 75.13% -65.623% 77.12% -83.691%
Net Profit Attributable To The Parent Company GR 3Y
-7.25% -72.446% 77.03% -19.088% 74.11% -67.551% 77.34% -83.083%
Total Assets GR 3Y
106.96% 0.354% 82.58% -1.337% -261.31% -5.095% -416.01% -7.673%
Share Equity Without Minority Interest GR 3Y
-64.02% -29.202% 35.27% -14.760% -50% -17.803% -108.72% -22.801%
Equity GR 3Y
-77.25% -23.417% 52.03% -9.821% -40.99% -13.211% -141.29% -20.473%
Total Liabilities GR 3Y
219.77% 114.127% -10.74% 36.480% -69.27% 35.690% -46.79% 40.868%
Basic Earning Per Share GR 3Y
-7.04% -72.299% 77.14% -18.991% 75.26% -67.543% 78.8% -83.075%
Net Assets Per Share GR 3Y
-58.43% -28.131% 35.91% -14.586% -69.84% -17.756% -653.35% -22.757%
Other Indicators
Currency Unit
港元港元港元港元

Q6、Q9、FY为累计季报:Q6 为中期报告;Q9 为第三季报;FY为年报。

环比数据来源于季报,环比 = (本期 - 上期)/上期 * 100%

公司概况 更多
四环医药控股集团有限公司是一家从事药品业务的香港投资控股公司。该公司主要在中国从事药品研发、制造及销售。其产品覆盖心脑血管、中枢神经系统、新陈代谢、肿瘤及抗感染领域。其产品包括克林澳、安捷利及欧迪美等心脑血管产品以及仁澳、甲硝唑及罗沙替丁等非心脑血管产品。
董事长: 车冯升
所属市场: 香港主板
上市日期: 2010/10/28
富途热股榜
港股美股沪深
交易热度搜索热度资讯热度
名称代码最新价涨跌幅

加载中...

自选
回到顶部